Screener
Bicara Therapeutics BCAX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -32.3%— | -30.9%— | -26.6%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 13.9×-10.8× | 14.6×-13.4× | 14.1×-21.9× | 25.8×— | 24.6×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $8.46+0.4% | $7.34-74.9% | $7.38-84.2% | $7.98+104% | $8.43+103% | |
| Valuation | ||||||
| Market capitalization | $1.2B+32.1% | $921.98M-2.7% | $861.55M— | $518.64M— | $710.44M— | |
| Price / book | 2.3×+0.1× | 2.3×+0.4× | 2.1×— | 1.2×— | 1.5×— |
FAQ
- Where do Bicara Therapeutics's ratios come from?
- Every ratio is computed from Bicara Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.